Tokyo/Works/Assay

From 2007.igem.org

(Difference between revisions)
Line 38: Line 38:
[[Image:hill IPTG.JPG|thumb|210px|'''Fig.2 The result of IPTG assay''' Fluorescence intensity as a function of the concentration of IPTG was determined. ]]
[[Image:hill IPTG.JPG|thumb|210px|'''Fig.2 The result of IPTG assay''' Fluorescence intensity as a function of the concentration of IPTG was determined. ]]
'''Purpose'''
'''Purpose'''
-
<br>check how LacI represses this hybrid promoter.  In order to adjust LacI repression<!--IPTGはLacIの濃度を調節しているわけではないのでconcentrationではなくrepressionに変更-->, IPTG was added.
+
By testing how LacI represses lux-lac hybrid promoter, parameters(n3,K3) should be decided. In order to adjust effective concentration of LacI, IPTG was added.  
-
<br>These parameters(n3,K3) is decided.
+
<br><br>
-
<!--<br>To determine the order of the concentration of IPTG necessary for the activation of our lux-lac hybrid promoter in the LacI producing pTrc99A cells.
+
-
<br> The order of the concentration is used for more detailed assay with narrower range of the IPTG concentration.-->
+
-
 
+
'''Result & Conclusion'''
'''Result & Conclusion'''
-
<br><!--As the concentration of IPTG increases, GFP fluorescence increased, indicating that the hybrid promoter in the LacI expressing cell became increasingly strengthened by decreasing repression by LacI. The activation graph in Fig. 2, the characteristics of the hybrid promoter expressed in Hill function is determined.-->
+
GFP fluorescence intensity was enhanced in IPTG-dose dependent manner. It indicates that the LacI repression was getting weak by adding IPTG. Taken together with the graph shown in Fig. 2 and the formulation of Hill function fitting described above, the characteristics of the hybrid promoter expressed in Hill function was determined.
-
The concentration of IPTG dose-denpendently increased GFP fluorescence. It indicates that the hybrid promoter in the cells expressing LacI became increasingly strengthened by decline of repression by LacI. The activation graph in Fig. 2, the characteristics of the hybrid promoter expressed in Hill function is determined.  
+
-
<br>
+
====⇒see more [[Tokyo/IPTG assay|details]]====
====⇒see more [[Tokyo/IPTG assay|details]]====
<br>
<br>

Revision as of 18:34, 26 October 2007


Works top  0.Hybrid promoter  1.Formulation  2.Assay1  3.Simulation  4.Assay2  5.Future works

Purpose of this assay  Effect of AHL  Effect of IPTG  Preliminary assays


Purpose of this assay (Hill function fitting)

We have obtained data for our newly devised hybrid promoter. By Hill function fitting, we have determined n2, n3, K2, and K3.


Ex6.4

Ex6.7
Ex6.11



⇒see more details

Effect of AHL


Fig.1 The result of AHL assay Fluorescence intensity (arbitrary unit, a.u.) as a function of the concentration of AHL was determined.

Purpose Bytesting how AHL activates lux-lac hybrid promoter, parameters(n2,K2) should be determined.

Result & Conclusion
GFP fluorescence increased in AHL-dose dependent manner, indicating that the hybrid promoter is enhanced by LuxR via AHL. Taken together with the graph shown in fig.1and formulation of Hill function fitting described above , the characteristics of the hybrid promoter expressed in Hill function, such as (n2,K2), is determined.


⇒see more details

2.IPTG assay

Fig.2 The result of IPTG assay Fluorescence intensity as a function of the concentration of IPTG was determined.

Purpose By testing how LacI represses lux-lac hybrid promoter, parameters(n3,K3) should be decided. In order to adjust effective concentration of LacI, IPTG was added.

Result & Conclusion GFP fluorescence intensity was enhanced in IPTG-dose dependent manner. It indicates that the LacI repression was getting weak by adding IPTG. Taken together with the graph shown in Fig. 2 and the formulation of Hill function fitting described above, the characteristics of the hybrid promoter expressed in Hill function was determined.

⇒see more details




Appendix: Preliminary assays

We conducted preliminary assays as practice experiments and check of materials and methods.

⇒See more details

Before(Formulation) << Assay1 >> Assay1 contents >>>> Simulation